ise-view-Article Detail Bottom List
SIS Medical opens new production facility to support its international growth
Date Published：1/12/2017 10:01:50 PM
SIS Medical AG has moved to its new production facility in Frauenfeld, Switzerland. From this new location, the company is capable of providing higher capacity to meet the increasing demand for balloon catheters in international markets. Following the move, significant investments will be made to strengthen its R&D department as well.
SIS Medical AG has set the course for growth. After having already achieved a leading market position in the field of high pressure and super high pressure balloons in Europe, the company is now preparing for a global approach. To achieve this, it has moved to a new cutting edge production facility at the company’s headquarters in Frauenfeld in the Canton of Thurgau, Switzerland.
During the coming quarters, the company will significantly increase its investments in the development of new products as well as international market registrations. Production in Frauenfeld has obtained ISO 13485 and ISO 9001 certification and is therefore providing the highest safety and quality standards.
SIS Medical currently employs 30 people and will significantly increase its number of employees in the months to come by hiring additional professionals, a number of which will include highly qualified R&D engineers.
SIS Medical’s high pressure balloons are in international demand by interventional cardiologists, as the products offer additional treatment options including the reopening of highly calcified arteries or the optimization of stent results, for example, in combination with the implantation of bioabsorbable stents for predilation and postdilation.
“With the new facility, we have established additional capacity with certified high quality and safety standards. This will serve as the foundation for significant additional international growth,” explained CEO and founder, Willi Zwahlen.
“SIS Medical is well positioned in its market, as demonstrated by its strong growth over the last few years. With the investment program for international registrations, we will be able to offer the innovative product portfolio to a number of new countries and further enhance R&D activities at the SIS headquarters,” added Hubertus Leonhardt, Chairman of the Board of Directors of SIS Medical and partner at the majority shareholder, SHS.